{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-024517","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2026-05-20T12:00:35+00:00","discovered_at":"2026-05-20T12:05:00.364588+00:00","generated_at":"2026-05-20T12:07:22.015001+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Telomir Pharma reports peer-reviewed Telomir-Zn data showing survival benefit in Wilson's disease model","bullets":["Telomir-Zn dose-dependently improved survival, reduced hepatic copper burden and liver injury biomarkers (ALT, AST, bilirubin) in zebrafish Wilson's disease model.","Preclinical study published in Advances in Redox Research; demonstrates reductions in oxidative stress, ROS-Ca²⁺ amplification, and tissue degeneration.","First peer-reviewed publication for Telomir-Zn in Wilson's disease; supports mechanism across copper-redox modulation and mitochondrial protection.","Telomir-Zn already has FDA IND clearance for Phase 1/2 in Triple-Negative Breast Cancer (April 2026); new data further validates platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-024517","json":"https://secwatch.observer/filing/0001493152-26-024517.json","markdown":"https://secwatch.observer/filing/0001493152-26-024517.md","text":"https://secwatch.observer/filing/0001493152-26-024517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226024517/0001493152-26-024517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226024517/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T12:07:22.015001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}